We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.17 | -0.39% | 43.60 | 8,231 | 12:44:51 |
From Sep 2019 to Sep 2024
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) said Friday that its majority-owned subsidiary, ViiV Healthcare, has submitted a marketing authorization application for a HIV therapy to the European Medicines Agency.
The U.K. pharmaceutical company said the application was submitted for the combined treatment--consisting of dolutegravir and lamivudine--based on the results of the two Gemini studies that included 1,400 adults with the disease.
"This regulatory submission, if approved, will make available a two-drug regimen option with dolutegravir and lamivudine instead of the traditional three-drug regimen and is an important step in the evolution of HIV treatment," said Deborah Waterhouse, chief executive officer of ViiV Healthcare.
ViiV Healthcare is majority-owned by Glaxo, with Pfizer Inc. (PFE) and Shionogi Limited also holding stakes.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
September 14, 2018 04:28 ET (08:28 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
